- Home
- IBRX vs EOSE Comparison
IBRX vs EOSE Comparison
Compare IBRX & EOSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- EOSE
- Stock Information
- Founded
- IBRX 2014
- EOSE 2008
- Country
- IBRX United States
- EOSE United States
- Employees
- IBRX N/A
- EOSE N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- EOSE Industrial Machinery/Components
- Sector
- IBRX Health Care
- EOSE Miscellaneous
- Exchange
- IBRX Nasdaq
- EOSE Nasdaq
- Market Cap
- IBRX 2.3B
- EOSE 2.3B
- IPO Year
- IBRX N/A
- EOSE N/A
- Fundamental
- Price
- IBRX $2.76
- EOSE $8.50
- Analyst Decision
- IBRX Strong Buy
- EOSE Buy
- Analyst Count
- IBRX 6
- EOSE 4
- Target Price
- IBRX $9.83
- EOSE $7.50
- AVG Volume (30 Days)
- IBRX 9.7M
- EOSE 11.9M
- Earning Date
- IBRX 11-11-2025
- EOSE 11-04-2025
- Dividend Yield
- IBRX N/A
- EOSE N/A
- EPS Growth
- IBRX N/A
- EOSE N/A
- EPS
- IBRX N/A
- EOSE N/A
- Revenue
- IBRX $56,600,000.00
- EOSE $33,800,000.00
- Revenue This Year
- IBRX $629.94
- EOSE $869.24
- Revenue Next Year
- IBRX $109.91
- EOSE $218.24
- P/E Ratio
- IBRX N/A
- EOSE N/A
- Revenue Growth
- IBRX 4227.22
- EOSE 128.49
- 52 Week Low
- IBRX $1.83
- EOSE $2.06
- 52 Week High
- IBRX $7.48
- EOSE $8.73
- Technical
- Relative Strength Index (RSI)
- IBRX 64.62
- EOSE 71.88
- Support Level
- IBRX $2.32
- EOSE $7.93
- Resistance Level
- IBRX $2.67
- EOSE $8.55
- Average True Range (ATR)
- IBRX 0.14
- EOSE 0.60
- MACD
- IBRX 0.05
- EOSE 0.11
- Stochastic Oscillator
- IBRX 72.73
- EOSE 89.31
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.